Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Foley

Showing results (61-70 of 87) with videos related to

Pageof 9
Sort By:
Surgery|September 10, 2002
Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national databaseJudd W Moul, Hongyu Wu, Leon Sun, et al.
Development (Cambridge, England)|March 15, 2017
Estrogen modulates mesenchyme-epidermis interactions in the adult nippleHsing-Jung Wu, Ji Won Oh, Dan F Spandau, et al.
The Journal of Urology|February 10, 2004
Watchful waiting and factors predictive of secondary treatment of localized prostate cancerHongyan Wu, Leon Sun, Judd W Moul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen eraCorey A Carter, Timothy Donahue, Leon Sun, et al.
Human Genetics|May 1, 2014
Homozygous truncating PTPRF mutation causes atheliaGuntram Borck, Liat de Vries, Hsin-Jung Wu, et al.
Science (New York, N.Y.)|July 17, 2025
In Science JournalsCourtney Malo, Angela Hessler, Phil Szuromi, et al.
Science (New York, N.Y.)|March 26, 2026
In Science JournalsDi Jiang, Sacha Vignieri, Angela Hessler, et al.
Neurology|September 14, 2019
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosingLana Zhovtis Ryerson, John Foley, Ih Chang, et al.
Advances in Therapy|November 21, 2024
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older PatientsYang Mao-Draayer, Amit Bar-Or, Konstantin Balashov, et al.
Science (New York, N.Y.)|January 15, 2026
In Science JournalsChristiana N Fogg, Jake S Yeston, Sacha Vignieri, et al.
Pageof 9

Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Surgery|September 10, 2002
Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national databaseJudd W Moul, Hongyu Wu, Leon Sun, et al.
Development (Cambridge, England)|March 15, 2017
Estrogen modulates mesenchyme-epidermis interactions in the adult nippleHsing-Jung Wu, Ji Won Oh, Dan F Spandau, et al.
The Journal of Urology|February 10, 2004
Watchful waiting and factors predictive of secondary treatment of localized prostate cancerHongyan Wu, Leon Sun, Judd W Moul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen eraCorey A Carter, Timothy Donahue, Leon Sun, et al.
Human Genetics|May 1, 2014
Homozygous truncating PTPRF mutation causes atheliaGuntram Borck, Liat de Vries, Hsin-Jung Wu, et al.
Science (New York, N.Y.)|July 17, 2025
In Science JournalsCourtney Malo, Angela Hessler, Phil Szuromi, et al.
Science (New York, N.Y.)|March 26, 2026
In Science JournalsDi Jiang, Sacha Vignieri, Angela Hessler, et al.
Neurology|September 14, 2019
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosingLana Zhovtis Ryerson, John Foley, Ih Chang, et al.
Advances in Therapy|November 21, 2024
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older PatientsYang Mao-Draayer, Amit Bar-Or, Konstantin Balashov, et al.
Science (New York, N.Y.)|January 15, 2026
In Science JournalsChristiana N Fogg, Jake S Yeston, Sacha Vignieri, et al.
Pageof 9